Comparative Study of Ormeloxifene and Medroxyprogesterone Acetate in Abnormal Uterine Bleeding

Area of Science:

• Gynecology
• Pharmacology
• Reproductive Medicine

Background:

• Abnormal uterine bleeding (AUB) is a common gynecological condition affecting women's quality of life.
• Current management strategies for AUB include hormonal and surgical interventions.
• Identifying effective and safe pharmacological options for AUB is crucial.

Purpose of the Study:

• To compare the efficacy of ormeloxifene with medroxyprogesterone acetate in treating abnormal uterine bleeding.
• To evaluate the impact of these treatments on bleeding patterns, hemoglobin levels, and endometrial thickness.
• To assess the safety and side effects associated with both medications.

Main Methods:

• A randomized study involving 440 patients with AUB.
• Group A received ormeloxifene (60 mg twice weekly for 3 months, then 60 mg weekly for 1 month).
• Group B received medroxyprogesterone acetate (10 mg twice daily from day 5-25 of the cycle). Assessments included PBAC scores, endometrial thickness, hemoglobin, and side effects.

Main Results:

• Both treatments significantly reduced the PBAC score and duration of bleeding.
• Ormeloxifene showed a 79.4% reduction in PBAC score, compared to 75% for medroxyprogesterone acetate.
• Both groups experienced increased hemoglobin levels and reduced endometrial thickness, with comparable side effect profiles.

Conclusions:

• Ormeloxifene is a highly effective first-line treatment for abnormal uterine bleeding.
• It is particularly suitable for perimenopausal women where amenorrhea may be an acceptable outcome.
• Ormeloxifene offers a favorable risk-benefit profile for AUB management.